Analyst firms · Oppenheimer · PRAX
Oppenheimer PRAX price target and rating history
Praxis Precision Medicines Inc. (PRAX) · Health Care
Oppenheimer rates Praxis Precision Medicines Inc. (PRAX) Outperform with a $750 price target, as of its latest action on Dec 15, 2025. It has published 3 rating actions on PRAX since August 2024, including 0 upgrades and 0 downgrades. Across 8 firms with a PRAX price target in the last 12 months, the median target is $474.50. Oppenheimer's $750 is 58% above that.
- Current rating
- Outperform
- Price target
- $750
- Median target, all firms
- $474.50
- Actions on PRAX
- 3
Oppenheimer price target on PRAX
Every Oppenheimer rating on PRAX
- Dec 15, 2025
- Jun 2, 2025
- Aug 5, 2024
How other firms rate PRAX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $706 | Oct 15, 2026 |
| Goldman Sachs | Buy | $447 | Jul 13, 2026 |
| RBC Capital Markets | Outperform | $449 | Jun 18, 2026 |
| Raymond James | Strong Buy | $815 | Apr 10, 2026 |
| Wolfe Research | Outperform | $500 | Feb 24, 2026 |
| Wells Fargo | Equal Weight | $282 | Feb 2, 2026 |
| Oppenheimer | Outperform | $750 | Dec 15, 2025 |
| BTIG | Buy | $424 | Nov 19, 2025 |
Questions about Oppenheimer and PRAX
- What is Oppenheimer's price target for PRAX?
- Oppenheimer's latest stated price target for Praxis Precision Medicines Inc. (PRAX) is $750, from its action on Dec 15, 2025.
- What is Oppenheimer's rating on PRAX?
- Oppenheimer rates PRAX Outperform, a bullish rating, as of Dec 15, 2025.
- When did Oppenheimer last change its view on PRAX?
- On Dec 15, 2025, Oppenheimer raises its price target to $750 from $250, keeps Outperform.
- How does Oppenheimer's PRAX target compare with other analysts?
- Across 8 firms with a PRAX price target in the last 12 months, the median target is $474.50. Oppenheimer's $750 is 58% above that.
All Oppenheimer ratingsPRAX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.